Effect of renal function loss on NT-proBNP level variations

Clinical Biochemistry

Volumn 42, Issue 10-11, 2009, Pages 1091-1098

  Bernstein, Larry H ^a   Zions, Michael Y ^a   Haq, Salman A ^a   Zarich, Stuart ^b   Rucinski, James ^a   Seamonds, Bette ^c,d   Berger, Stanley ^c,d   Lesley, Daniel Y ^e   Fleischman, William ^f   Heitner, John F ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

^c Mercy Fitzgerald Hospital   (United States)

^d Mercy Hospital of Philadelphia   (United States)

^e LAC+USC Medical Center   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cardiac troponin T; CHF; Congestive heart failure; Estimated glomerular filtration rate; MDRD; Modification of Diet in Renal Disease; N terminal pro B type natriuretic peptide; NT proBNP; Renal insufficiency; Transthoracic echocardiogram

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN; TROPONIN T;

ADULT; AGE; ARTICLE; CHEMOLUMINESCENCE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ELECTRONIC MEDICAL RECORD; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

AGE DISTRIBUTION; AGED; DIET; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 67349234503     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.02.027     Document Type: Article

References (42)

1. Dao Q., Krishnaswamy P., Kazanegra R., et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. J. Am. Coll. Cardiol. 37 (2001) 379-385
2. Morrison L.K., Harrison A., Krishnaswamy P., Kazanegra R., Clopton P., and Maisel A. Utility of rapid natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol. 39 (2003) 202-209
3. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347 (2002) 161-167
4. Januzzi J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal NT-proBNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95 (2005) 948-954
5. Mockel M., Muller R., Vollert J., et al. Role of N-terminal pro-B-type natriuretic peptide in risk stratification in patients presenting in the emergency room. Clin. Chem. 51 9 (2005) 1624-1631
6. Masson S., Latini R., and Anand I.S. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin. Chem. 52 8 (2006 Aug) 1528-1538 [Electronic publication 2006 Jun 15]
7. Mueller T., Gegenhueber A., Dieplinger B., et al. Long-term stability of endogenous B-type natriuretic (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin. Chem. Lab. Med. 42 8 (2004) 942-944
8. Tsutamoto T, Wada A, Meada K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96:506-516.
9. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HEFT). Circulation 107 (2003) 1278-1283
10. Omland T., Richards A.M., Wergeland R., and Vik-Mo H. B-type natriuretic peptide and long term survival in patients with stable coronary artery disease. Am. J. Cardiol. 95 (2005) 24-28
11. Omland T., Aakvaag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic dysfunction and long term prognosis after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93 (1996) 1963-1969
12. de Lemos J.A., Morrow D.A., Bently J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N. Engl. J. Med. 345 (2001) 1014-1021
13. Richards A.M., Nicholls M.G., Espiner E.A., et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107 (2003) 2786-2792
14. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
15. Luchner A., Hengstenberg C., Löwel H., et al. N-terminal pro-brain natriuretic peptide after myocardial infarction. Hypertension 39 (2002) 99-104
16. Vickery S., Price C.P., John I.R., Abbas N.A., Webb M.C., Kempson M.E., and Lamb E.J. B-type natriuretic peptide (BNP) and amino-terminal proBNP in Patients with CKD: relationship to renal function and left ventricular hypertrophy. Am. J. Kidney Dis. 46 (2005) 610-620
17. Januzzi J.L., van Kimmenade R., Lainchbury J., Bayes-Genis A., et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur. Heart J. 27 3 (2006) 330-337
18. DeFilippi C.R., Seliger S.L., Maynard S., and Christenson R.H. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin. Chem. 53 (2007) 1511-1519
19. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Intern. Med. 30 (1999) 461-469
20. Cochroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
21. Burkhardt H., Hahn T., Gretz N., and Gladisch R. Bedside estimation of the glomerular filtration rate in hospitalized elderly patients. Nephron, Clin. Pract. 101 (2005) 1-8
22. Hallan S., Astor B., and Lydersen S. Estimating glomerular filtration rate in the general population: the second Health Survey of Nord-Trondelag (HUNT II). Nephrol. Dial. Transplant. 21 (2006) 1525-1533
23. Wieczowska-Tobias K., Niemir Z., Guzik P., Breborowicz A., and Oreopoulis D. Difference in estimated GFR with two different formulas in elderly individuals. Int. Urol. Nephrol. 38 (2006) 381-385 29
24. Wasen E., Isoaho R., Mattila K., Vahlberg T., and Kivela S.L. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J. Intern. Med. 256 (2004) 70-78
25. Januzzi Jr. J.L., Sakhuja M., O'Donoghue A.L., Baggish S., Anwaruddin C.U., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med. 166 (2006) 315-320
26. Hoersch S., and Katus H.A. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation 110 (2004) 1780-1786
27. Pfister R., Diedrichs H., Schiedermair A., Rosenkranz S., Hellmich M., Erdmann E., and Schneider C.A. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur. J. Heart Fail. 10 3 (2008 Mar) 224-225
28. Omland T., Persson A., Ng L, O'Brien R., Karlsson T., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndrome. N. Engl. J. Med. 345 (2001) 1014-1021
29. Olsen M.H., Wachtell K., Nielsen O.W., Hall C., Wergeland R., Ibsen H., Kjeldsen S., Devereux R.B., Dahlof B., and Hildebrandt P. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J. Hypertens. 24 8 (2006) 1531-1539
30. Olsen M.H., Hansen T.W., Christensen M.K., Gustafsson F., Rasmussen S., Wachtell K., Ibsen H., Torp-Pedersen C., and Hildebrandt P. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J. Hypertens. 26 1 (2008) 26-34
31. Rosenberg J., Schou M., Gustafsson F., Badskjær J., and Hildebrandt P. Prognostic threshold levels of NT-proBNP testing in primary care. Eur. Heart J. 30 1 (2009) 66-73
32. Gardner R.S., Özalp F., Murday A.J., Robb S.D., and McDonagh T.A. N-terminal pro-brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J. 24 19 (2003) 1735-1743
33. Ndrepepa G., Braun S., Niemoller K., Mehilli J., von Beckerat N., et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 112 (2005) 2102-2107
34. Lonn E., Gerstein H.C., Smieja M., Mann J.F.E., and Yusuf S. Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. Eur. Heart J. Suppl. 5 Suppl A (2003) A43-A48
35. McKie P.M., Rodeheffer R.J., Cataliotti A., Martin F.L., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47 (2006) 874-880
36. Omland T, Sabatine MS, Jablonski KA, Rice MM, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease. The PEACE Trial. J Am Coll Cardiol;50(3): 205-21.
37. Marz W., Tiran B., Seelhorst U., Wellnitz B., Bauersachs J., et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: The Ludwigshafen Risk and Cardiovascular Health Study. Clin. Chem. 53 (2007) 1075-1083
38. Januzzi Jr. J.L., Sakhuja R., O'Donoghue M., Baggish A.L., Anwaruddin S., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med. 166 (2006) 315-320
39. Bibbins-Domingo K., Gupta R., Na B., Wu A.H.B., Schiller N.B., and Whooley M.A. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297 (2007) 169-176
40. Hogenhuis J., Voors A.A., Jaarsma T., Hoes A.W., Hillege H.L., et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur. J. Heart Fail. 7 1 (2007) 81-86
41. Raymond I., Groenning B.A., Hildebrandt P.R., Nilsson J.C., Baumann M., Trawinski J., and Pedersen F. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89 (2003) 745-751
42. McCullough P.A., Duc P., Omland T., McCord J., Nowak R.M., Hollander J.E., Herrmann H.C., Steg P.G., Westheim A., Knudsen C.W., et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am. J. Kidney Dis. 41 (2003) 571-579